Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Breast Neoplasms
  • Doxorubicin
  • Immunotoxins

abstract

  • The BR96-doxorubicin immunoconjugate has limited clinical antitumor activity in metastatic breast cancer. The gastrointestinal toxicities likely represent binding of the agent to normal tissues expressing the target antigen and may have compromised the delivery of the immunoconjugate to the tumor sites.

publication date

  • February 1999

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 10080588

Additional Document Info

start page

  • 478

end page

  • 84

volume

  • 17

number

  • 2